In line with this, House et al. identified a unique macrophage gene signature (including CXCL10 and CXCL11) that was more prevalent in melanoma patients responding to immune checkpoint blockade (ICB) since it was associated with a higher IFNG gene signature [30]. This evidence concerns the gene IFNG and melanoma.